NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
About 62% of NeuBase Therapeutics' investor base is looking to short. The analysis of current outlook of investing in NeuBase Therapeutics suggests that many traders are alarmed regarding NeuBase Therapeutics' prospects. The current market sentiment, together with NeuBase Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use NeuBase Therapeutics stock news signals to limit their universe of possible portfolio assets.
NeuBase |
Data show that Stealth Editors achieve ex vivo gene editing using simple synthetic reagents to harness the cells own high-fidelity editing machineryData show that Stealth Editors do not elicit a
Read at benzinga.com
 |
NeuBase Therapeutics Fundamental Analysis
We analyze NeuBase Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
NeuBase Therapeutics is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
NeuBase Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NeuBase Therapeutics stock to make a market-neutral strategy. Peer analysis of NeuBase Therapeutics could also be used in its relative valuation, which is a method of valuing NeuBase Therapeutics by comparing valuation metrics with similar companies.
Peers
NeuBase Therapeutics Related Equities
| NAMS | NewAmsterdam Pharma | 41.41 | ||||
| CNSP | Cns Pharmaceuticals | 10.00 | ||||
| CMPX | Compass Therapeutics | 7.88 | ||||
| ZVSA | ZyVersa Therapeutics | 3.92 | ||||
| PHGE | Biomx | 1.59 | ||||
| IVA | Inventiva | 0.38 | ||||
| CGEM | Cullinan Oncology | 1.18 | ||||
| SONN | Sonnet Biotherapeutics | 5.71 | ||||
| GLUE | Monte Rosa | 7.45 | ||||
| IMMX | Immix Biopharma | 13.78 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |